Tag: COVID vaccine

Man arrested for posing as health ministry official, duping people of Rs 15 crore

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

A 49-year-old man has been arrested for allegedly posing as a senior Union Health Ministry official and duping six people of Rs 15 crore on the pretext of providing work orders for Covid vaccine transportation, police said on Thursday.

Umesh Batra was arrested by the Economic Offences Wing of the Delhi Police. Batra used to work for a construction company but his financial situation took a hit during the lockdown and he resorted to cheating people after joining hands with the kingpin behind the scam Harmenn Sabherwal, Govind Tulshyan and three other people, all of whom have been arrested, they said.

Police said a probe was initiated after several complaints were received from people who claimed to have been duped of Rs 3 to 4 crore on the pretext of providing work orders for transportation of Covid vaccines.

Also Read: Coal Minister Pralhad Joshi opens Rs 300-crore Odisha rail link to expedite fuel delivery

After a preliminary enquiry, a case was registered and an investigation was taken up. Six complainants came forward and the total amount they were duped off came out to be Rs 15 crore, they said.

Deputy Commissioner of Police (EOW) M I Haidar said the investigation revealed that in May 2021, the accused contacted the complainants and offered them work orders from the Ministry of Health and Family Welfare for transportation of Covid vaccines.

“To gain their trust, the accused took the victims to the ministry, which is located on the premises of Nirman Bhavan. They posed as officers of the ministry and obtained the signatures of the complainants on forged work orders. In lieu of those fake work orders, they received Rs 15 crore from the complainants,” he said.

Analysis of bank accounts and other details of the accused revealed huge cash deposits, Haidar added.

Also Read: CBI raids 91 locations to probe alleged registration of foreign medical graduates with fake certificates

“Batra used to pose as an officer of the Ministry of Health who worked from a conference room. He was roped in by another accused, Prafulla Kumar Nayak. Batra was absconding from his home, and continuous raids and searches were being conducted to trace and arrest him,” he said.

On December 21, Batra surrendered before a Delhi court and he was arrested, the officer added.

Batra disclosed that Vinod Kumar Sharma and Vinay Gupta too used to pose as officers of the ministry, he said.

Also Read: Dhoot, Kochhar and her husband sent to judicial custody till Jan 10 – Here is how the case moved

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Smartwatch data shows Covid booster vaccine is safe: Lancet study

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The booster dose of COVID-19 vaccine is safe, according to a study published in The Lancet Respiratory Medicine that monitored heart measures through smartwatches.

Researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years.

Of those monitored, 2,038 received the booster dose of the COVID-19 vaccine, allowing the researchers to objectively compare measures before and after the participants took the vaccine, and confirm the safety of the vaccine.

The team also examined the safety of the booster by analysing the medical files of 250,000 members of Maccabi Health Services anonymously.

Also Read: Fitness gear maker beatXP enters smartwatch segment, targets 10% market share by 2023

They were able to evaluate the safety of the vaccines from three perspectives: subjectively — what the participant reports, objectively — what the watch detects, and clinically — what the doctor diagnoses.

“The smartwatches were used to monitor a number of parameters such as heart rate, variation in heart activity, quality of sleep, number of daily steps taken, and more,” said Professor Dan Yamin from Tel Aviv University.

“We saw clear and significant changes after administration of the vaccine, such as an increase in heart rate compared to the pulse rate measured before vaccination, and then we saw a return to the participant’s baseline, i.e., the pulse levels after vaccination returned to their previous levels after six days. Hence, our study confirms the safety of the vaccine,” Yamin said.

The researchers said the most surprising finding was that the watches were more sensitive than the people they were monitoring. Many participants reported fatigue, headache, etc. after receiving the vaccine, and after two or three days reported that they felt normal and well, they said.

“In contrast, from examining their watches, we saw distinct changes in heart rate that continued for several more days,” Yamin said.

“There were also vaccinated participants who did not report any side effects at all and yet definitely experienced physiological changes, based on data from their smartwatches. In other words, we learned that the smartwatches were more sensitive to changes in general feeling than the participants themselves,” he added.

In the medical literature, 25 unusual side effects attributed to the COVID vaccine were reported, and the researchers paid special attention to look for rare cases of inflammation of the heart muscle (myocarditis) and pericarditis.

The researchers checked the frequency of these unusual side effects among a quarter of a million Maccabi members and found no increase in serious incidents of any kind associated with vaccination.

Also Read: Garmin India launches “Give A Garmin” offer on wellness smartwatches

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Hetero’s COVID-19 oral drug Nirmacom gets WHO prequalification

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Hetero, a Hyderabad-based leading pharmaceutical company on Monday announced the receipt of World Health Organisation Prequalification of Medicines Programme (WHO PQ) approval for its generic version of COVID-19 oral anti-viral treatment candidate Nirmatrelvir.

A press release from the drug maker said it is the first prequalification for a generic version of Pfizer’s COVID-19 oral anti-viral drug ‘Paxlovid,’ which the WHO called, the best therapeutic choice for high-risk patients to date.

WHO made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission, such as unvaccinated, aged or immunosuppressed patients, it said.

The combi pack, launched by Hetero as Nirmacom, will contain Nirmatrelvir 150 mg (2 tablets) and Ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Nirmacom will be manufactured at Hetero’s facilities in India, the release said.

Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies, said: “WHO Prequalification for Nirmacom is a significant milestone in the fight against COVID-19 as it allows us to expand access to this important innovative antiretroviral drug to people in need. We are committed to making Nirmacom available faster at affordable prices across 95 LMICs including India.”

Hetero entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer’s COVID-19 oral anti-viral treatment candidate Nirmatrelvir, which is co-packaged with Ritonavir (Nirmatrelvir; Ritonavir), in LMICs (low and middle income countries).

Also Read:COVID-19 in India: RT-PCR to be made mandatory for flyers arriving from these countries

Charles Gore, Executive Director of MPP said: “We are delighted to see the first generic version of Nirmatrelvir under MPP licence with Pfizer, receive quality assurance approval from WHO. This is an impressive achievement from Hetero as we announced the sub-licence agreements just nine months ago.

With cases of COVID-19 again on the rise we need to make treatments readily available in LMICs so no one is left behind.” Hetero has already received Emergency Use Authorisation (EUA) approval from the Drugs Controller General of India (DCGI) to manufacture and market Nirmacom, the release added.

Also Read:Random COVID-19 sampling of international passengers arriving in India starts as cases surge worldwide

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

China to introduce second COVID vaccine booster for elderly and high-risk groups

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

China’s National Health Commission (NHC) on Wednesday announced that it will begin distributing a second vaccine booster shot against COVID-19 to high-risk groups and seniors citizens above the age of 60.

According to the NHC statement, individuals with serious underlying illnesses and those with poor immunity are eligible to receive the second shot. There must be a six-month interval between the first and second booster doses, it added.

China has been trying to expedite vaccinations for people over 60 since it prepped to substantially loosen severe COVID-19 prevention measures earlier this month.

After three years of enforcing some of the most stringent virus restrictions in the world, the Chinese government made the unexpected announcement earlier this week that it was eliminating several of the restrictions.

Protests over the curbs last month in Beijing and other cities turned into calls for leader Xi Jinping and the Communist Party to step down, a degree of popular discontent unseen in decades.

Also read: China axes travel tracking app in latest easing of COVID curbs

While met with relief, the relaxation has also sparked concerns about a new wave of infections potentially overwhelming health care resources in some areas. The loosening of restrictions resulted in a substantial decline in testing but cases still seem to be rising quickly with many people conducting tests at home and avoiding hospitals.

Without asymptomatic cases being counted, China reported just 2,249 “confirmed” infections Wednesday, bringing the nation’s total to 369,918 — more than double the level on Oct. 1. It has recorded 5,235 deaths — compared with 1.1 million in the United States.

However, the government-provided statistics from China have not been independently validated, and it has been questioned if the Communist Party in power has attempted to reduce the number of cases and fatalities.

Also read: China COVID situation: Long queues at fever clinics as country mulls expanding hospitals, ICUs

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificates.

The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company to manufacture and distribute the intranasal vaccine globally.

“Since iNCOVACC has been approved for “Restricted use under emergency situation” and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID,” the sources told PTI.

Also Read: PM Modi to inaugurate Mopa international airport in Goa, address World Ayurveda Congress

Currently Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, Russian Sputnik V and Biological E Ltd’s Corbevax are listed in the CoWIN portal.

The vaccine maker, on September 6, announced that its iNCOVACC (BBV154), the world’s first intranasal COVID-19 vaccine has received approval from the Drugs Controller General of India under Restricted Use in Emergency Situation for ages 18 and above.

“There have been no requests for procurement from state or central governments,” sources further said.

The city-based vaccine maker also plans to export iNCOVACC to other countries once it gets approvals from the respective nations, sources added.

iNCOVACC (BBV154) has also received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.

Also Read: AstraZeneca’s global chairman reflects on 3 billion COVID shots and what’s next

The vaccine was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated it in pre-clinical studies for efficacy.

The vaccine candidate underwent Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.

Phase-III trials were conducted for safety, and immunogenicity in approximately 3,100 subjects, at 14 trial sites across India.

Also Read: Alembic Pharma receives EIR for Gujarat unit and approval for skin infection cream from USFDA

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

AstraZeneca’s global chairman reflects on 3 billion COVID shots and what’s next

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

In April next year, Leif Johansson, will retire as AstraZeneca’s non-executive chairman, marking the end of a more than decade long journey that saw the British drug giant ride over many a storm — including the COVID-19 pandemic — and emerge stronger. Earlier this year, the company completed the delivery of three billion doses of the COVID-19 vaccine just 18 months after its partnership for manufacturing with the University of Oxford.

CNBC-TV18’s Shereen Bhan spoke to Leif Johansson, Global Chairman, AstraZeneca, to discuss his experience and learning from arguably the biggest challenge that the pharma industry faced in decades, the status of the Oxford-AstraZeneca COVID-19 vaccine, and plans for India.

Speaking about key learnings from the pandemic, Johansson said when it came to innovation, AstraZeneca, as a company — along with academia and the government — needs to find new ways to cooperate. He said, “Also there is a lesson there, that normally a combination of academia, companies, corporations, and government can learn from that by saying we can probably do 2x or 3x bigger, greater speed.”

He added, “The industry spends about $200 billion per year in research and development — all of that actually comes from the selling of the drugs. So we are now in innovative patented phase.”

Read Here: Sun Pharma maintains current year revenue guidance despite Halol import alert

Johansson felt there is an opportunity to think differently at different unique times. He said, “This pandemic was unique enough to justify a not-for-profit decision, but also a very strong spreading of technology and technology transfer into many countries and this is a very unique experience and situation.”

He added, “It is also important to recognise that industry needs to be able to generate revenue to be able to fund research for future medicines.”

Also Read: DCGI approves shipment of SII-produced Ebola vaccine to Uganda

During the COVID times, AstraZeneca decided that this was a unique situation to stay away from the profit principles and focus on really getting things done in a short while. He said, “The fact that we did technology transfer, but also the fact that we did it for no profit, made it easy to work around the world. So we ended up delivering three billion doses of vaccine in more than 180 countries. And of course, that is something that we think is good, and that we are proud of.”

Watch video for more.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Bharat Biotech’s COVID-19 vaccine iNCOVACC gets CDSCO nod for heterologous booster doses

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Bharat Biotech International Limited on Monday announced that its COVID-19 intranasal vaccine iNCOVACC (BBV154) has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.

A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.

The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, it said. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, Bharat Biotech said.

Also read: Bharat Biotech’s COVID-19 nasal vaccine booster gets emergency use authorisation

The vaccine had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for primary two-dose schedule. Phase-III trials were conducted for safety, immunogenicity in approximately 3,100 subjects, at 14 trial sites across India.

Krishna Ella, Chairman & Managing Director, Bharat Biotech, said: “Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases… We have also initiated development of variant-specific vaccines for COVID for future preparedness.”

iNCOVACC was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.

Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, “The DCGI’s approval of Bharat Biotech’s intranasal vaccine iNCOVACC (BBV154) to be used as a heterologous booster dose against currently available COVID-19 vaccines is a moment of great pride for our country. This move will further strengthen our collective fight against the pandemic and broaden vaccine coverage.”

Also read: Cyrus Poonwalla turns 4th richest Indian, thanks to bumper profits from Covid-19 vaccines

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

China launches a COVID-19 vaccine inhaled through the mouth

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

The Chinese city of Shanghai started administering an inhalable COVID-19 vaccine on Wednesday, in what appears to be a world first.

The vaccine, a mist that is sucked in through the mouth, is being offered for free as a booster dose for previously vaccinated individuals, according to an announcement posted on an official city social media account.

Needle-free vaccines may persuade people who don’t like getting a shot to get vaccinated, as well as help expand vaccination in economically-weaker countries because they are easier to administer.

China doesn’t have vaccine mandates but wants more people to get booster shots before it relaxes strict pandemic restrictions that are holding back the economy and increasingly out of sync with the rest of the world.

A video posted by an online Chinese state media outlet showed people at a community health centre sticking the short nozzle of a translucent white cup into their mouths. Accompanying text said that after slowly inhaling, one individual held his breath for five seconds, with the entire procedure completed in 20 seconds.

“It was like drinking a cup of milk tea,” one Shanghai resident said in the video. “When I breathed it in, it tasted a bit sweet.”

Also Read: These market watchers are excited about the pharma space – Here are their other near-term bets

A vaccine taken in the mouth could also fend off the virus before it reaches the rest of the respiratory system, though that would depend in part on the size of the droplets, an expert said.

Larger droplets would train defenses in parts of the mouth and throat, while smaller ones would travel further into the body, said Dr. Vineeta Bal, an immunologist in India.

Chinese regulators approved the vaccine for use as a booster in September. It was developed by Chinese biopharmaceutical company Cansino Biologics Inc. as an aerosol version of the same company’s one-shot adenovirus vaccine, which uses a relatively harmless cold virus.

Cansino has said the inhaled vaccine has completed clinical trials in China, Hungary, Pakistan, Malaysia, Argentina and Mexico.

Regulators in India have approved a nasal vaccine, another needle-free approach, but it has yet to be rolled out. The vaccine, developed in the US and licensed to Indian vaccine maker Bharat Biotech, is squirted in the nose.

About a dozen nasal vaccines are being tested globally, according to the World Health Organization.

Also Read: Brain Fog: Know all about this COVID-19 symptom

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

India records over 12,800 new COVID-19 cases, highest in 112 days; fatalities at 14

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India registered 12,847 new COVID-19 cases in the last 24 hours — the highest in 112 days and 634 more than the previous day. With fresh cases, the country’s overall caseload has mounted to 4,32,70,577, the Ministry of Health and Family Welfare said early Friday.

India has been witnessing a spike in COVID-19 cases for a few weeks now. The country had crossed the 7,000-mark on June 9, the 8,000 mark on June 11, and the 12,000 mark on June 16.

Maharashtra continues to report the maximum number of COVID-19 cases in the last 24 hours with 4,255 fresh infections — highest daily count since February 12. This was followed by Kerala with 3,419 cases, Delhi with 1,323 cases, Karnataka with 833 cases, and Tamil Nadu with 552 cases.

ALSO READ | 732 million people can take COVID booster shots but haven’t. Here’s why

Mumbai reported 2,366 new coronavirus-positive cases and two deaths, which pushed its overall infection tally to 10,88,248 and the fatality count to 19,578, the Brihanmumbai Municipal Corporation (BMC) said. The city saw 73 more cases as compared to the previous day when there were 2,293 infections.

Moreover, 14 more deaths due to COVID-19 were reported in the last 24 hours, pushing the nationwide toll to 5,24,817, the ministry said. Of these 14 deaths, two were reported in Delhi, one in Karnataka, eight in Kerala, and three in Maharashtra.

With fresh cases and deaths, the active caseload increased by 4,848 to 63,063. As of Friday, the active cases constituted 0.15 percent of the total caseload.

Meanwhile, the daily COVID-19 positive rate stood at 2.47 percent, the weekly positive rate at 2.41 percent, and the recovery rate at 98.64 percent on Friday. The number of people who have recovered from the disease rose to 4,26,82,697.

ALSO READ | Coronavirus in India: Over 12,000 COVID-19 cases recorded in 24 hours — highest in 4 months

Meanwhile, as many as 15,27,365 more COVID-19 vaccines were administered in the last 24 hours, taking the total vaccinations to 1,95,84,03,471. On Thursday, members of the government advisory panel NTAGI agreed on reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said. A recommendation for it will be made to the Health Ministry soon, they said.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Pfizer COVID-19 shot appears effective for kids under 5, says USFDA

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

Pfizer’s kid-sized doses appear to be safe and effective for children under five, US federal health officials said on Sunday. 

It comes at a time when kids under the age of five are the only group not eligible for vaccination. The US Food and Drug Administration (USFDA) posted its analysis of the Pfizer shot ahead of a Wednesday meeting where experts will vote on whether the shots are ready for the nation’s 18 million children.

Last week, a similar analysis of  Moderna’s vaccine for kids under six was posted by the USFDA.

Also read: Pfizer Says 3 Covid-19 Shots Protect Children Under 5 

Parents in the US have long been advocating for vaccinating their children against the virus. If regulators clear the shots by one or both companies, vaccinations could begin as soon as next week. with the drug makers ready to rapidly ship doses ordered by the government. 

According to USFDA analysis, only about 3 percent of US COVID cases are in the age group 6 months to 4 years. The analysis also shows that hospitalisation and death rates in this group are higher than those for older children. Pfizer is offering doses beginning at 6 months through 4 years and Moderna is offering doese through 5 years.

Also read:  Moderna Says Its Low-Dose Covid-19 Shots Work For Kids Under 6 Years 

The USFDA further said that high levels of virus-fighting antibodies were developed in the children receiving the three-shot series vaccine, exactly the threshold needed for authorisation.

Moderna, on the other hand, is working on a booster shot after its two-dose series was found only 40 percent to 50 percent effective, though the two companies shots were tested at different times.

For the youngest children, each company is offering different dose sizes and numbers of shots.

On Wednesday, the USFDA will ask an independent panel of vaccine experts to debate both companies’ data before voting. Its not a compulsion for the USFDA is to follow the group’s recommendations.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow